Boston Biomedical Oncology Pipeline
Below is a list of ongoing clinical and preclinical studies involving investigational compounds from Boston Biomedical. Click through to learn more about the studies, including eligibility criteria and study locations.
*Active, not recruiting.
Napabucasin is also known as BBI-608. Amcasertib is also known as BBI-503.
Ombipepimut-S and adegramotide/nelatimotide are the nonproprietary names for DSP-7888.
AML=acute myeloid leukemia; CML=chronic myeloid leukemia; MDS=myelodysplastic syndrome; MM=multiple myeloma; NSCLC=non-small cell lung cancer.
All compounds are investigational agents, and their safety and efficacy have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
To learn more about Boston Biomedical's Expanded Access and Compassionate Use Policy, please visit our guidelines.